

AN

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 5/06, C07C 323/60 A61K 37/02, 31/16	A1	(11) International Publication Number: WO 93/21211 (43) International Publication Date: 28 October 1993 (28.10.93)
(21) International Application Number: PCT/EP93/00866 (22) International Filing Date: 7 April 1993 (07.04.93) (30) Priority data: P 9200809 14 April 1992 (14.04.92) ES (71) Applicant (for all designated States except US): LABORATORIOS MENARINI S.A. [ES/ES]; Alfonso XII, 587, E-08912 Badalona (ES). (72) Inventors; and (75) Inventors/Applicants (for US only): CARGANICO, Germano [IT/ES]; MAULEON CASELLAS, David [ES/ES]; GARCIA PEREZ, Maria Luisa [ES/ES]; Alfonso XII, 587, E-08912 Badalona (ES). (74) Agent: MINOJA, Fabrizio; Studio Consulenza Brevettuale, Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: AMIDES HAVING INHIBITING ACTIVITY ON PHOSPHOLIPASE A ₂ , A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM <div style="display: flex; justify-content: space-around; align-items: center;"> <div data-bbox="552 1323 868 1575" style="text-align: center;"> $\begin{array}{c} \text{R}^2 \quad \text{H}_2\text{C}-\text{X}-\text{R}^1 \\ \quad \\ \text{N}-\text{CH} \\ \quad \\ \text{C}-\text{NH}-\text{CH}-\text{R}^4 \\ \quad \quad \\ \text{O} \quad \text{R}^3 \end{array}$ <p>(I)</p> </div> <div data-bbox="990 1323 1258 1585" style="text-align: center;"> $\begin{array}{c} \text{R}^6 \quad \text{H}_2\text{C}-\text{X}-\text{R}^1 \\ \quad \\ \text{N}-\text{CH} \\ \quad \\ \text{C}-\text{OH} \\ \quad \\ \text{O} \end{array}$ <p>(II)</p> </div> </div> (57) Abstract <p>The present invention relates to amides of general formula (I), a process for the preparation thereof and pharmaceutical compositions containing them. In formula (I), X is oxygen or sulphur; R¹ is alkyl; R² is hydrogen, alkylcarbonyl, alkoxy-carbonyl or alkylsulfonyl or the corresponding arylalkyl groups; R³ is hydrogen, carboxyl, alkoxy-carbonyl or aryloxy-carbonyl; and R⁴ hydrogen, alkyl, arylalkyl, heteroarylalkyl, hydroxyalkyl, thioalkyl, alkylthioalkyl, aminoalkyl, carboxyalkyl, carbamoyl, guanidinoalkyl or sulfoalkyl. Said compounds inhibit phospholipase A₂, therefore they can be used as antiinflammatory, antiallergic, antithrombotic, antiasthmatic agents and in the prevention of anaphylactic shock. Said amides can be obtained by reacting a compound (II), wherein R⁶ is the same as R² or a suitable protecting group, with a suitable amine H₂NCHR³R⁴, in the presence of a proton-binding base and a carboxy-activating agent.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

AMIDES HAVING INHIBITING ACTIVITY ON PHOSPHOLIPASE A₂
A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTI-
CAL COMPOSITIONS CONTAINING THEM

FIELD OF THE INVENTION

The present invention relates to novel amides, a process for the preparation thereof, the pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them.

Said amides have inhibiting action on phospholipase A₂.

TECHNOLOGICAL BACKGROUND

It is well established that the major part of eicosanoids, prostaglandins and related compounds derive from a C₂₀ fatty acid, having 4 insaturations, which is named arachidonic acid (AA), which is mainly obtained esterifying the hydroxy group at the 2-position of glycerophospholipids contained in cell membranes. AA is released from the phospholipid containing it by the action of a lipase, i.e. phospholipase A₂ (PLA₂) ("CRC Handbook of Eicosanoids and Related Lipids", vol. (II), Ed. A. L. Willis, CRS Press, Inc. Florida (1989)). After the release, AA is metabolized in mammals through different pathways or enzyme systems. Through cyclooxygenase, AA gives rise to prostaglandins and thromboxanes, the most significant being PGE₂ and TxA₂, which participate directly in inflammation (Higgs et al. Annals of Clinical Research, 16, 287-299 (1984)). Through lipoxygenase, AA produces leukotrienes, the most important being LTB₄, LTC₄ and LTD₄, which also participate in inflammatory reactions, showing chemotactic activities, stimulate segregation of

lysosomal enzymes and act as important factors in the immediate hypersensitivity reactions (Bailey and Casey, Ann. Rep. Med. Chem., 17, 203-217 (1982)).

By the action of PLA_2 , besides the release of
5 fatty acids, the corresponding lysophospholipids are obtained, which either can then be re-esterified or be converted into PAF (platelet activating factor) by acetylation at 2-position, if they have phosphocholine at the 3-position, an ether bond at the 1-position and
10 are in a cell system having acetyl-transferase activity. PAF is also a pro-inflammatory agent, that has been ascribed to play an important role in various pathological processes, such as asthma, anaphylaxis, inflammation and ischemia (Braquet et al., Pharmacol.
15 Rev., 39 (2), 97 (1987)).

PLA_2 , besides being related to the inflammatory processes, can also be involved, either directly or indirectly, in degenerative thrombotic and cancerous pathologies.

20 From what stated above, it is evident that PLA_2 is of great importance in controlling the production of the mediators involved in the pathologies indicated above. As a consequence, compounds inhibiting PLA_2 provide a new rational approach for the prevention, elimi-
25 nation or improvement of different allergic, anaphylactic, asthmatic, inflammatory and thrombotic conditions.

Various compounds have been described to be in vi-
tro inhibitors of PLA_2 (Wilkerson, Drugs of the Future, 15, 141 (1990)), however nowadays there are no specific
30 PLA_2 inhibitors for the clinical use.


The compounds of general formula (I) are not

structurally related to any PLA₂ inhibitor described in literature. Some compounds that could be considered structurally related to the compounds of the present invention are not included in formula (I) and show very different activities, for example some of them are receptor inhibitors of LTC₄, (Sala et al., Eicosanoids, 3, 105 (1990)), or of glutathione S-transferase (Adang et al., J. Biol. Chem., 266, 830 (1991)), or they enhance the immune activity (JP 55085553); or they are S-butylglutathione-like metabolites (James et al., Biochem. J. 109, 727 (1968)).

Up to now, corticosteroids are the only medications considered likely to exert an inhibitory mechanism on PLA₂, even though in an indirect way. However, said compounds have a series of adverse systemic side-effects which restrict the use thereof, particularly in chronic pathologies. PLA₂ selective inhibitors, such as the compounds of the present invention, advantageously have the same effectiveness as corticosteroids, without the side-effects thereof.

DISCLOSURE

The compounds of the present invention have the following general formula (I)




I

wherein:

- X is an oxygen or sulphur atom;


- R^1 is a C_4 - C_{20} straight or branched alkyl group;
- R^2 is hydrogen or a R^5 -CO-, R^5 -O-CO- or R^5 -SO₂- group, in which R^5 is a C_1 - C_{20} straight or branched alkyl group, phenyl or an arylalkyl group of less than 20 carbon atoms totally;
- R^3 is hydrogen, a carboxy group, an alkoxycarbonyl, aryloxy carbonyl or arylalkoxycarbonyl group of less than 10 carbon atoms in the last three cases;
- R^4 is hydrogen, a C_1 - C_6 straight or branched alkyl group, an arylalkyl group of less than 10 carbon atoms, an heteroarylalkyl group of less than 10 carbon atoms, an hydroxyalkyl group of less than 4 carbon atoms, a thioalkyl or alkylthioalkyl group of less than 4 carbon atoms, an aminoalkyl group of less than 6 carbon atoms, the amino group being in the free or derivatized form, as an alkyl amide of less than 4 carbon atoms, a C_2 - C_5 carboxyalkyl group, the carboxy group being in the free or derivatized form as an alkyl or aralkyl ester of less than 8 carbon atoms, a carbamoylalkyl group of less than 4 carbon atoms, a guanidinoalkyl group of less than 5 carbon atoms, or a sulfoalkyl group of less than 4 carbon atoms; with the proviso that R^4 cannot be hydrogen when R^3 is hydrogen or when R^1 is C_4 alkyl and R^2 is hydrogen or acetyl.

When R^2 is hydrogen, the compounds of formula (I) can be obtained in form of salts, as represented by formula (Ia)



wherein X^- is a pharmaceutically acceptable anion of an inorganic acid (e.g. hydrochloric or sulfuric) or organic carboxylic acid (e.g. acetic, trifluoroacetic, lactic or tartaric), or organic sulfonic acid (e.g. methanesulfonic, ethanesulfonic or toluenesulfonic).

When R^3 is a carboxy group, the compounds of formula (I) can also be obtained in form of salts, as represented by formula (Ib)



15 wherein M^+ is an alkali metal cation (e.g. Na^+ , K^+), or the equivalent of an alkaline-earth metal cation (e.g. $1/2 Ca^{2+}$, $1/2 Mg^{2+}$).

When the compounds of formula (I) have more than one basic nitrogen, the double acid addition salts can also be obtained (e.g. dihydrochlorides or dihydrobromides). Similarly, when the compounds of formula (I) have more than one carboxylic or sulfonic acid group, the double base addition salts can also be obtained (e.g. sodium, potassium, calcium or magnesium salts).

25 The compounds of general formula (I) have one or more asymmetric carbons in their structure. The present invention includes all the possible stereoisomers as well as the mixtures thereof.

In the compounds of general formula (I), R^1 can be for example butyl, hexyl, decyl, tetradecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl or icosyl; when R^2 is

30

a R^5 -CO-, R^5 -O-CO- or R^5 -SO₂-, in which R^5 is an alkyl or arylalkyl group, this can be methyl, ethyl, propyl, butyl, decyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, icosyl, benzyl or 11-phenylundecyl; when R^3 is an alkoxy-carbonyl, aryloxy-carbonyl or arylalkoxy-carbonyl group, they can be methoxy-carbonyl, ethoxy-carbonyl, propyloxy-carbonyl, phenoxy-carbonyl or benzyloxy-carbonyl; when R^4 is an alkyl group, this can be methyl, isopropyl, butyl, isobutyl or sec-butyl; when R^4 is an arylalkyl group, this can be benzyl or p-hydroxybenzyl; when R^4 is an heteroarylalkyl group, this can be 4-imidazolylmethyl or 3-indolylmethyl; when R^4 is an hydroxyalkyl group, this can be hydroxymethyl, 1-hydroxyethyl or 2-hydroxyethyl; when R^4 is a thioalkyl or alkylthioalkyl group, this can be mercaptomethyl or 2-methylthioethyl; when R^4 is an aminoalkyl group, this can be 4-aminobutyl, 3-aminopropyl or 4-acetylaminobutyl; when R^4 is a carboxyalkyl group, this can be carboxymethyl, 2-carboxyethyl, 3-carboxypropyl, methoxycarbonylmethyl or 2-methoxycarbonyl-ethyl; when R^4 is a carbamoylalkyl group, this can be carbamoylmethyl or 2-carbamoylethyl; when R^4 is a guanidinoalkyl group, this can be 2-guanidinoethyl or 3-guanidinopropyl; when R^4 is a sulfoalkyl group, this can be sulfomethyl, 2-sulfoethyl or 3-sulfopropyl.

Preferred compounds of the present invention are those in which:

- X and R^1 are the groups defined above;
- R^2 is hydrogen, a C₁-C₂₁ alkoxy-carbonyl group atoms, preferably groups acetyl, hexanoyl, dodecanoyl or hexadecanoyl;

- R³ is hydrogen, a carboxy group or an alkoxy-carbonyl group of less than 10 carbon atoms, preferably methoxy-carbonyl or ethoxycarbonyl;


- R⁴ is hydrogen, a C₁-C₆ straight or branched alkyl group, preferably methyl or isobutyl, an hydroxyalkyl group of less than 4 carbon atoms, preferably hydroxymethyl or 2-hydroxyethyl, an aminoalkyl or alkylcarbonylaminoalkyl group of less than 7 carbon atoms totally, preferably 4-aminobutyl or 4-acetylaminobutyl, a C₂-C₅ carboxyalkyl group, preferably carboxymethyl or 2-carboxyethyl, or a sulfoalkyl of less than 4 carbon atoms, preferably sulfomethyl.

Particularly preferred compounds of the present invention are the following:

- 15 N-Hexanoyl-O-octadecyl-D-serinyl-L-valine.
N-Hexadecanoyl-O-decyl-D-serinylglycine.
N-Acetyl-O-octadecyl-D-serinyl-L-glutamic acid.
N-Acetyl-O-octadecyl-D,L-serinyl-L-glutamic acid.
N-Acetyl-O-octadecyl-D-serinyl-D-glutamic acid.
- 20 N-Acetyl-O-octadecyl-D,L-serinyl-L-leucine.
N-Acetyl-O-octadecyl-D,L-serinyl-D,L-leucine.
N-Acetyl-O-octadecyl-D-serinyl-L-leucine.
N-Hexadecanoyl-S-decyl-D-cysteinyl-L-lysine.
N-Acetyl-S-octadecyl-D-cysteinyl-L-lysine.
- 25 S-Octadecyl-D-cysteinylglycine (hydrobromide).
S-Octadecyl-D-cysteinyl-L-lysine (hydrobromide).
S-Octadecyl-L-cysteinyl-L-lysine (hydrobromide).
S-Octadecyl-D-cysteinyl-D-lysine (hydrobromide).
S-Octadecyl-L-cysteinyl-D-lysine (hydrobromide).
- 30 S-butyl-D-cysteinyl-L-glutamic acid (hydrobromide).
S-Butyl-D-cysteinyl-L-leucine (hydrobromide).

- S-Butyl-D-cysteinyl-L-lysine (hydrobromide).
 N-Acetyl-S-octadecyl-D-cysteinyl-L-leucine.
 N-Acetyl-S-octadecyl-D,L-cysteinyl-D,L-leucine.
 N-Acetyl-S-octadecyl-D-cysteinylglycine.
- 5 Methyl N-acetyl-S-octadecyl-D-cysteinyl-L-glutamate.
 N-Acetyl-S-octadecyl-D-cysteinyl-L-glutamic acid.
 N-Acetyl-S-octadecyl-D-cysteinyl- ϵ -N-acetyl-L-lysine.
 N-Acetyl-S-octadecyl-L-cysteinyl- ϵ -N-acetyl-L-lysine.
 N-Acetyl-S-octadecyl-D-cysteinyl- ϵ -N-acetyl-D-lysine.
- 10 N-Acetyl-S-octadecyl-L-cysteinyl- ϵ -N-acetyl-D-lysine.
 N-Acetyl-S-octadecyl-D-cysteinyl-L-serine.
 N-Acetyl-S-octadecyl-D-cysteinyl-L-homoserine.
 N-Dodecanoyl-S-butyl-D-cysteinyl-L-glutamic acid.
 N-Dodecanoyl-S-butyl-D-cysteinyl-L-leucine.
- 15 N-Acetyl-S-butyl-D-cysteinyl- ϵ -N-acetyl-L-lysine.
 N-Acetyl-S-octadecyl-D,L-cysteinyltaurine (sodium salt).
 N-Acetyl-S-decyl-D,L-cysteinyltaurine (sodium salt).
 N-Acetyl-S-octadecyl-D-cysteinyltaurine (sodium salt).
- 20 N-Acetyl-S-octadecyl-D-serinyltaurine (sodium salt).

According to the present invention, the compounds of general formula (I) can be prepared by reacting a compound of formula (II), of suitable stereochemistry at the carbon at the 2-position




II

wherein X and R^1 are the groups defined above and R^6


can be equivalent to the group R^2 above or, if R^2 in formula (I) is hydrogen, then R^6 is a suitable amino-protecting group, for example benzyloxycarbonyl or tert-butyloxycarbonyl, with:

- 5 a) When in (I) R^3 is one of the groups defined above, except for hydrogen, and R^4 is one of the groups defined above, except for a sulfoalkyl group, a reactive of formula (III), of suitable stereochemistry,



- wherein R^7 can be equivalent to R^3 in formula (I), except for hydrogen, and, when in (I) R^3 is a carboxy group, then R^7 is a suitably protected carboxy group, for example in form of the benzyl or tert-butyl ester, and R^8 can be the same as R^4 , except when in formula (I) R^4 contains a functional group in the free form, in which case in R^8 such a group is suitably protected, for example when R^4 in formula (I) contains an amino group, R^8 in formula (III) can contain a benzyloxycarbonylamino or tert-butyloxycarbonylamino group; when R^4 in (I) contains a carboxy group, this is for example in form of the benzyl or tert-butyl ester in (III); the reaction between (II) and (III) is carried out in the presence of a proton-binding base, such as triethylamine or pyridine and a carboxy-activating agent, such as dicyclohexylcarbodiimide or pivaloyl chloride, in suitable aprotic solvents such as chloroform, methylene chloride or N,N-dimethylformamide, at a temperature from 0° to 40°C for a time from 3 to 24 hours, to obtain an intermediate of formula (IV)

10




IV


wherein X, R¹, R⁶, R⁷ and R⁸ are the groups described above. This compound of formula (IV) is converted into (I) by removing any protecting groups present in R⁶, R⁷ and R⁸, according to conventional methods; when R⁶ and R⁷ are benzyloxycarbonyl groups and a benzyloxycarbonylamino or a benzyloxycarbonyl group can be present in R⁸, the benzyl groups can be removed by catalytic hydrogenation with Pd-C or with Pd(OH)₂, in solvents such as methanol, water or acetic acid, under hydrogen pressures from atmospheric pressure to 50 psi, at a temperature from 20° to 50°C for a time from 3 to 20 hours; or in an acid medium, for example with hydrobromic or trifluoroacetic acid, in a suitable solvent such as acetic acid or chloroform, at a temperature from 0° to 40°C for a time from 15 minutes to 6 hours; when R⁶ and R⁷ are tert-butyloxycarbonyl groups and a tert-butyloxycarbonylamino or tert-butyloxycarbonyl group can be present in R⁸, the tert-butyl groups can be removed under the same acid conditions as mentioned above. If R⁶ in formula (IV) is an amino-protecting group, such as benzyloxycarbonyl or tert-butyloxycarbonyl, this is deprotected to obtain compounds of formula (I) wherein R² is hydrogen, which can in their turn be converted into the compounds (I) with R² different from hydrogen by an acylation or sulfonylation reaction with suitable acid

halides or anhydrides (R^5COX , R^5OCOX or R^5SO_2X).

b) When in (I) R^3 is hydrogen and R^4 is a sulfoalkyl group of less than 4 carbon atoms, a compound of formula (II) is reacted with a carboxy-activating agent such as N-hydroxy-5-norbornen-2,3-dicarboxymide acid or N-hydroxysuccinimide in the presence of a dehydrating agent such as dicyclohexylcarbodiimide, in a suitable solvent such as dioxane, tetrahydrofuran or N,N-dimethylformamide, at a temperature from 0° to 40°C for a time from 5 to 24 hours. Subsequently, it is reacted with a reactive (V)



wherein R^4 is a sulfoalkyl group of less than 4 carbon atoms, in the presence of a base such as sodium bicarbonate or aqueous sodium hydroxide, in a suitable organic solvent such as dioxane or tetrahydrofuran at a temperature from 0°C to the solvent's reflux, for a time from 5 to 24 hours, to obtain a compound of formula (VI)



VI

wherein X, R^1 , R^4 and R^6 are group described above. When R^6 is the same as R^2 , this compound (VI) coincides with compound (I) wherein R^3 is hydrogen and with the proviso that R^2 is hydrogen. When R^6 is an amino-protecting group, this compound can be transformed into compound (I) wherein R^2 is hydrogen, by means of con-

ventional deprotection methods, or optionally it can be converted into the remaining compounds (I), as indicated above.


Finally, if a salt of (I) is desired, a treatment with a suitable acid, base or ion exchanger is carried out, according to conventional methods.

A starting compound (II) wherein X is sulphur can be prepared, for example, following the synthetic sequence shown in Scheme 1.

10

Scheme 1

15



A compound of formula (VIII) wherein R^6 is one of the groups defined above can be obtained (step a) starting from cysteine ((VII)) of suitable stereochemistry, this product being commercially available in both the chiral D or L forms and the racemic one, by reaction with a suitable acyl or sulfonyl halide R^6Y , wherein R^6 is the group described above and Y can be iodide, chloride or bromide, in the presence of a base such as triethylamine, sodium acetate or sodium bicarbonate, in a suitable solvent such as water or N,N-dimethylformamide, at a temperature from 0°C to the solvent's reflux, for a time from 1 to 12 hours.


30

A compound of formula (II) can be obtained (step b) by reacting the compound (VIII) with a compound ZR^1 ,

13

wherein R^1 is the group described above and Z is a suitable leaving group, such as for example bromide, iodide, mesylate or tosylate in the presence of a base such as potassium hydroxide or sodium carbonate, in a suitable organic solvent such as ethanol or N,N-dimethylformamide, at a temperature from 0° to 50°C, for a time from 5 to 24 hours.

A starting compound (II) wherein X is oxygen can be prepared, for example, following the synthetic sequence shown in Scheme 2.

Scheme 2

A compound of formula (X) can be prepared, for example, starting from compound (IX), the preparation of which is well described in literature (Hajdu et al. J. Org. Chem. 48, 1197 (1983)), by means of a process already described in Spanish Patent application N° 9101610.

A compound of formula (XI), wherein R^1 and R^6 are the groups defined above, can be obtained (step d), by

means of reaction with a suitable acyl or sulfonyl halide as described above.

A compound of formula (II) wherein X is oxygen can be prepared, for example, by subjecting a compound (XI) to the action of an oxidizing agent such as the system formed by $\text{RuCl}_3 \cdot 3\text{H}_2\text{O}/\text{NaIO}_4$, in mixtures of suitable solvents such as carbon tetrachloride:acetonitrile:water (3:3:2) or carbon tetrachloride:ethyl acetate:water (3:3:2), at a temperature from -20° to 30°C , for a time from 15 min to 18 hours.

The compounds of the present invention show a marked activity as inhibitors of PLA_2 activity, and accordingly they have antiinflammatory and antiallergic properties which make them useful for the treatment of diseases in which this enzyme is involved. For this purpose, said compounds can be used in human therapy for the prevention and treatment of allergic rhinitis, bronchial asthma, hypersensitivity reactions such as allergic conjunctivitis, various inflammatory conditions such as those present in rheumatoid arthritis, osteoarthritis, tendinitis, bursitis, psoriasis and other related inflammations.

For the therapeutical uses, the compounds of the present invention are formulated in the appropriate pharmaceutical form, according to conventional techniques and excipients, such as those described in Remington's Pharmaceutical Science Handbook, Mack Pub. Co., N.Y., USA. Examples of said forms include capsules, tablets, syrups and the like, containing from 1 to 1000 mg per unitary dose.

The following examples illustrate the preparation

and the pharmacological activity of the compounds of the present invention.

EXAMPLE 1

N-Benzyloxycarbonyl-D-cysteine ((VIII), $R^6 = \text{COOCH}_2\text{C}_6\text{H}_5$).

5 A solution of D-cysteine (1.50 g, 8.54 mmol) in water (5 ml) is added, at 0°C, with 1M NaHCO_3 (25.62 ml) and 1.32 ml (9.41 mmol) of benzyl chloroformate. The mixture is stirred at 0°C for 4 h. After that, it is left at room temperature and the benzyl chloroformate excess is removed by means of extraction with ethyl ether. The resulting aqueous phase is acidified with concentrated hydrochloric acid to pH=3, extracted with ethyl acetate, dried and solvent is removed, to obtain the title compound in an 87% yield.

10 T.L.C.: eluent chloroform:methanol:acetic acid, 65:25:3, $R_f=58$
15 N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 3.01 (m, 2H); 4.68 (m, 1H); 5.08 (s, 2H); 7.35 (broad s, 5H).

EXAMPLE 2

20 N-Benzyloxycarbonyl-L-cysteine ((VIII), $R^6 = \text{COOCH}_2\text{C}_6\text{H}_5$).

Following the process described in example 1, starting from L-cysteine, the title compound was prepared in a 93 % yield.

25 T.L.C.: eluent chloroform:methanol:acetic acid, 65:25:3, $R_f=0.58$
N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 3.01 (m, 2H); 4.68 (m, 1H); 5.08 (s, 2H); 7.35 (broad s, 5H).

EXAMPLE 3

N-Benzyloxycarbonyl-S-octadecyl-D-cysteine
30 ((II), $X=\text{S}$, $R^1=(\text{CH}_2)_{17}\text{CH}_3$, $R^6=\text{COOCH}_2\text{C}_6\text{H}_5$).

A solution of N-benzyloxycarbonyl-D-cysteine (1.67

g, 6.51 mmol) in ethanol (13.4 ml) is added with 0.36 g (6.51 mmol) of KOH dissolved in ethanol (13.4 ml) under inert atmosphere. The mixture is cooled to 5°C and 1-bromooctadecane (2.17 g, 6.51 mmol) and 0.36 g more of
5 KOH in ethanol are added. The mixture is stirred at room temperature for 24 h. Subsequently, water (100 ml) is added to the mixture, which is acidified with concentrated hydrochloric acid to pH=3-4, extracted with ethyl acetate, dried and solvent is removed, to obtain
10 a crude product which is purified by flash chromatography on silica gel column. Eluting with chloroform:methanol, 20:1, 2.44 g of the title compound are obtained as a white solid melting at 79-81°C (74% yield).

15 $[\alpha]_D^{20} = -7.5^\circ$ (c=1.164, CHCl₃).

T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f = 0.76$

N.M.R. ¹H (300 MHz, CDCl₃) δ ppm: 0.85 (t, 3H); 1.25 (m, 30H); 1.51 (m, 2H); 2.49 (t, 2H); 2.98 (d, 2H);
20 4.58 (m, 1H); 5.10 (s, 2H); 7.30 (m, 5H).

EXAMPLE 4

N-Benzylloxycarbonyl-S-octadecyl-L-cysteine

((II), X=S, R¹=(CH₂)₁₇CH₃, R⁶=COOCH₂C₆H₅).

Following the process described in example 3,
25 starting from N-benzylloxycarbonyl-L-cysteine and 1-bromooctadecane the title compound was prepared, 78-81°C (87% yield).

$[\alpha] = +7.6^\circ$ (c=1.163, CHCl₃)

T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f = 0.76$
30

N.M.R. ¹H (300 MHz, CDCl₃) δ ppm: 0.85 (t, 3H); 1.25

(m, 30H); 1.51 (m, 2H); 2.49 (t, 2H); 2.98 (d, 2H); 4.58 (m, 1H); 5.10 (s, 2H); 7.30 (m, 5H).

EXAMPLE 5

N-Benzyloxycarbonyl-S-butyl-D-cysteine

5 ((II), X=S, $R^1=(CH_2)_3CH_3$, $R^6=COOCH_2C_6H_5$).

Following the process described in example 3, starting from N-benzyloxycarbonyl-D-cysteine and 1-bromobutane, the title compound was prepared in a 73 % yield.

10 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.44$

N.M.R. 1H (300 MHz, $CDCl_3$) δ ppm: 0.85 (t, 3H); 1.32 (m, 2H); 1.50 (m, 2H); 2.49 (t, 2H); 2.98 (d, 2H); 4.58 (m, 1H); 5.10 (s, 2H); 7.30 (m, 5H).

15

EXAMPLE 6

Benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinyl- γ -benzyl-L-glutamate ((IV), X=S, $R^1=(CH_2)_{17}CH_3$, R^6 and $R^7=COOCH_2C_6H_5$, $R^8=CH_2CH_2COOCH_2C_6H_5$).

A mixture of N-benzyloxycarbonyl-S-octadecyl-D-cysteine (0.250 g, 0.49 mmol), L-glutamic acid dibenzyl ester (p-toluenesulfonate) (0.244 g, 0.49 mmol) and methylene chloride (15 ml) is added, at 0°C, with triethylamine (0.068 ml, 0.49 mmol) and dicyclohexylcarbodiimide (0.109 mg, 0.53 mmol). The mixture is stirred at room temperature for 3 h. Thereafter it is added with some drops of glacial acetic acid, stirred for 30 min and the formed dicyclohexylurea is filtered off. The filtrate is washed with water, dried and the volatiles are evaporated off, to obtain a crude product which is purified by flash chromatography on a silica gel column. Eluting with petroleum ether:chloroform,

20

25

30

1:1, 0.323 g of the title compound are recovered in form of a colourless oil (82% yield).

T.L.C.: ethyl ether, 2:1, $R_f = 0.68$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.80 (t, 3H); 1.23 (m, 30H); 1.47 (m, 2H); 2.00 (m, 1H); 2.16 (m, 1H); 2.31 (m, 2H); 2.45 (m, 2H); 2.75 (m, 2H); 4.24 (m, 1H); 4.57 (m, 1H); 5.01 (s, 2H); 5.04 (s, 2H); 5.08 (d, 2H); 7.26 (m, 15H).

EXAMPLE 7

10 Benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinyl-L-leucinate ((IV), $\text{X}=\text{S}$, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, R^6 and $\text{R}^7=\text{COOCH}_2\text{C}_6\text{H}_5$, $\text{R}^8=\text{CH}_2\text{CH}(\text{CH}_3)_2$).

According to the procedure described in example 6 starting from N-benzyloxycarbonyl-S-octadecyl-D-cysteine and benzyl L-leucinate (hydrochloride), the title compound was prepared as a colourless oil (88% yield).

T.L.C.: eluent ethyl ether, $R_f = 0.77$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.85 (t, 9H); 1.24 (m, 30H); 1.56 (m, 5H); 2.50 (m, 2H); 2.79 (dd, 1H); 2.92 (dd, 1H); 4.31 (m, 1H); 4.60 (m, 1H); 5.10 (m, 4H); 7.30 (m, 10H).

EXAMPLE 8

25 Benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinylglycinate ((IV), $\text{X}=\text{S}$, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, R^6 and $\text{R}^7=\text{COOCH}_2\text{C}_6\text{H}_5$, $\text{R}^8=\text{H}$).

According to the procedure described in example 6, starting from N-benzyloxycarbonyl-S-octadecyl-D-cysteine and benzyl glycinate (hydrochloride), the title compound was prepared as a colourless oil (76% yield).

T.L.C.: eluent ethyl ether, $R_f = 0.66$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.90 (t, 3H); 1.21 (m, 30H); 1.56 (m, 2H); 2.50 (m, 2H); 2.82 (dd, 1H); 2.96 (dd, 1H); 4.06 (m, 2H); 4.36 (m, 1H); 5.11 (s, 2H); 5.16 (s, 2H); 7.32 (m, 10H).

5

EXAMPLE 9

Benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinyl- ϵ -N-benzyloxycarbonyl-L-lysinate ((IV), X=S, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, R^6 and $\text{R}^7=\text{COOCH}_2\text{C}_6\text{H}_5$, $\text{R}^8=(\text{CH}_2)_4\text{NHCOOCH}_2\text{C}_6\text{H}_5$).

According to the procedure described in example 6, starting from N-benzyloxycarbonyl-S-octadecyl-D-cysteine and benzyl ϵ -N-benzyloxycarbonyl-L-lysinate (hydrochloride), the title compound was prepared as a colourless oil (77% yield).

T.L.C.: eluent ethyl ether, $\text{R}_f = 0.67$

15 N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.86 (t, 3H); 1.25 (m, 30H); 1.40-1.90 (complex signal, 8H); 2.48 (m, 2H); 2.84 (m, 2H); 3.05 (m, 2H); 4.30 (m, 1H); 4.58 (m, 1H); 5.10 (m, 6H); 7.30 (m, 15H).

EXAMPLE 10

20 Benzyl N-benzyloxycarbonyl-S-octadecyl-L-cysteinyl- ϵ -N-benzyloxycarbonyl-L-lysinate ((IV), X=S, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, R^6 and $\text{R}^7=\text{COOCH}_2\text{C}_6\text{H}_5$, $\text{R}^8=(\text{CH}_2)_4\text{NHCOOCH}_2\text{C}_6\text{H}_5$).

According to the procedure described in example 6, starting from N-benzyloxycarbonyl-S-octadecyl-L-cysteine and benzyl ϵ -N-benzyloxycarbonyl-L-lysinate (hydrochloride), the title compound was prepared as a colourless oil (80% yield).

T.L.C.: eluent ethyl ether, $\text{R}_f = 0.67$

30 N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.86 (t, 3H); 1.25 (m, 30H); 1.40-1.90 (complex signal, 8H); 2.48 (m, 2H); 2.84 (m, 2H); 3.05 (m, 2H); 4.30 (m, 1H); 4.58 (m, 1H);

5.10 (m, 6H); 7.30 (m, 15H).

EXAMPLE 11

Benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinyl- ϵ -N-benzyloxycarbonyl-D-lysinate ((IV), X=S,
 5 $R^1=(CH_2)_{17}CH_3$, R^6 and $R^7=COOCH_2C_6H_5$,
 $R^8=(CH_2)_4NHCOOCH_2C_6H_5$).

According to the procedure described in example 6, starting from N-benzyloxycarbonyl-S-octadecyl-D-cysteine and benzyl ϵ -N-benzyloxycarbonyl-D-lysinate
 10 (hydrochloride), the title compound was prepared as a colourless oil (84% yield).

T.L.C.: eluent ethyl ether, $R_f = 0.67$

N.M.R. 1H (300 MHz, $CDCl_3$) δ ppm: 0.86 (t, 3H); 1.25 (m, 30H); 1.40-1.90 (complex signal, 8H); 2.48 (m, 2H);
 15 2.84 (m, 2H); 3.05 (m, 2H); 4.30 (m, 1H); 4.58 (m, 1H);
 5.10 (m, 6H); 7.30 (m, 15H).

EXAMPLE 12

Benzyl N-benzyloxycarbonyl-S-octadecyl-L-cysteinyl- ϵ -N-benzyloxycarbonyl-D-lysinate ((IV), X=S, $R^1=(CH_2)_{17}CH_3$,
 20 R^6 and $R^7=COOCH_2C_6H_5$, $R^8=(CH_2)_4NHCOOCH_2C_6H_5$).

According to the procedure described in example 6, starting from N-benzyloxycarbonyl-S-octadecyl-L-cysteine and benzyl ϵ -N-benzyloxycarbonyl-D-lysinate (hydrochloride), the title compound was prepared as a
 25 colourless oil (79% yield).

T.L.C.: eluent ethyl ether, $R_f = 0.67$

N.M.R. 1H (300 MHz, $CDCl_3$) δ ppm: 0.86 (t, 3H); 1.25 (m, 30H); 1.40-1.90 (complex signal, 8H); 2.48 (m, 2H);
 2.84 (m, 2H); 3.05 (m, 2H); 4.30 (m, 1H); 4.58 (m, 1H);
 30 5.10 (m, 6H); 7.30 (m, 15H).

EXAMPLE 13

Benzyl N-benzyloxycarbonyl-S-butyl-D-cysteinyl- γ -benzyl-L-glutamate ((IV), X=S, $R^1=(CH_2)_3CH_3$, R^6 and $R^7=COOCH_2C_6H_5$, $R^8=CH_2CH_2COOCH_2C_6H_5$).

5 According to the procedure described in example 6, starting from N-benzyloxycarbonyl-S-butyl-D-cysteine and L-glutamic acid dibenzyl ester (p-toluenesulfonate), the title compound was prepared as a colourless oil (92 % yield).

10 T.L.C.: eluent ethyl ether, $R_f=0.57$

N.M.R. 1H (300 MHz, $CDCl_3$) δ ppm: 0.88 (t, 3H); 1.35 (m, 2H); 1.50 (m, 2H); 2.02 (m, 1H); 2.24 (m, 1H); 2.40 (m, 2H); 2.50 (m, 2H); 2.88 (m, 2H); 4.39 (m, 1H); 4.69 (m, 1H); 5.10 (m, 6H); 7.26 (m, 15H).

15

EXAMPLE 14

Benzyl N-benzyloxycarbonyl-S-butyl-D-cysteinyl-L-leucinate ((IV), X=S, $R^1=(CH_2)_3CH_3$, R^6 and $R^7=COOCH_2C_6H_5$, $R^8=CH_2CH(CH_3)_2$).

20 According to the procedure described in example 6, starting from N-benzyloxycarbonyl-S-butyl-D-cysteine and benzyl L-leucinate (hydrochloride), the title compound was prepared as a colourless oil (96 % yield).

T.L.C.: eluent ethyl ether, $R_f=0.57$

25 N.M.R. 1H (300 MHz, $CDCl_3$) δ ppm: 0.87 (m, 9H); 1.34 (m, 2H); 1.58 (m, 5H); 2.50 (m, 2H); 2.86 (m, 2H); 4.37 (m, 1H); 4.64 (m, 1H); 5.08 (m, 4H); 7.28 (m, 10H).

EXAMPLE 15

30 Benzyl N-benzyloxycarbonyl-S-butyl-D-cysteinyl- ϵ -N-benzyloxycarbonyl-L-lysinate ((IV), X=S, $R^1=(CH_2)_3CH_3$, R^6 and $R^7=COOCH_2C_6H_5$, $R^8=(CH_2)_4NHCOOCH_2C_6H_5$).

According to the procedure described in example 6,

starting from N-benzyloxycarbonyl-S-butyl-D-cysteine and benzyl ϵ -N-benzyloxycarbonyl-L-lysinate (hydrochloride), the title compound was prepared as a colourless oil (85 % yield).

5 T.L.C.: eluent ethyl ether, $R_f=0.38$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.85 (t, 3H); 1.20-1.90 (complex signal, 10H); 2.48 (t, 2H); 2.70 (dd, 1H); 2.88 (dd, 1H); 3.08 (m, 2H); 4.30 (m, 1H); 4.59 (m, 1H); 5.10 (m, 6H); 7.30 (m, 15H).

10

EXAMPLE 16

Benzyl S-octadecyl-D-cysteinyl-L-glutamate (hydrobromide) ((I), X=S, $R^1=(\text{CH}_2)_{17}\text{CH}_3$, $R^2=\text{H}$, $R^3=\text{COOCH}_2\text{C}_6\text{H}_5$, $R^4=\text{CH}_2\text{CH}_2\text{COOH}$).

15 A mixture of benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinyl- δ -benzyl-L-glutamate (0.328 g, 0.40 mmol) and hydrobromic acid in 33% glacial acetic acid (4 ml) is stirred at room temperature for 30 min. After that, the mixture is evaporated to dryness to obtain the title compound as a colourless oil (100% yield).

20 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.10$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.89 (t, 3H); 1.29 (m, 30H); 1.60 (m, 2H); 2.02 (m, 1H); 2.22 (m, 1H); 2.43 (m, 2H); 2.62 (m, 2H); 3.00 (m, 2H); 4.10 (m, 1H); 4.54 (m, 1H); 5.19 (m, 2H); 7.34 (m, 5H).

25

EXAMPLE 17

Benzyl S-octadecyl-D-cysteinyl-L-leucinate (hydrobromide) ((I), X=S, $R^1=(\text{CH}_2)_{17}\text{CH}_3$, $R^2=\text{H}$, $R^3=\text{COOCH}_2\text{C}_6\text{H}_5$, $R^4=\text{CH}_2\text{CH}(\text{CH}_3)_2$).

30

According to the procedure described in example 16, starting from benzyl N-benzyloxycarbonyl-S-octa-

decyl-D-cysteinyl-L-leucinate, the title compound was prepared as a colourless oil (95 % yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.47$

5 N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.85 (m, 6H); 1.20 (m, 30H); 1.56 (m, 5H); 2.58 (m, 2H); 3.15 (m, 2H); 3.74 (m, 1H); 4.50 (m, 1H); 5.28 (q, 2H); 7.30 (m, 5H).

EXAMPLE 18

S-Octadecyl-D-cysteinylglycine (hydrobromide)

10 ((I), X=S, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2=\text{H}$, $\text{R}^3=\text{COOH}$, $\text{R}^4=\text{H}$).

According to the procedure described in example 16, starting from benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinylglycinate and after 4 h stirring at room temperature, the title compound was prepared (90 % yield).

15 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.12$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.92 (t, 3H); 1.29 (m, 30H); 1.72 (m, 2H); 2.63 (t, 2H); 2.88 (dd, 1H);
20 3.12 (dd, 1H); 4.00 (s, 2H); 4.06 (m, 1H).

EXAMPLE 19

S-Octadecyl-D-cysteinyl-L-lysine (hydrobromide)

((I), X=S, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2=\text{H}$, $\text{R}^3=\text{COOH}$, $\text{R}^4=(\text{CH}_2)_4\text{NH}_2$).

According to the procedure described in example 18, starting from benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinyl- ϵ -N-benzyloxycarbonyl-L-lysinate, the title compound was prepared as a white solid which decomposes at 158°C (99 % yield).

25 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.17$

30 N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.30

(m, 30H); 1.49-2.02 (complex signal, 8H); 2.65 (t, 2H); 2.89 (dd, 1H); 2.84 (t, 2H); 3.18 (dd, 1H); 4.16 (m, 1H); 4.44 (m, 1H).

EXAMPLE 20

5 S-Octadecyl-L-cysteinyl-L-lysine (hydrobromide)
((I), X=S, $R^1=(CH_2)_{17}CH_3$, $R^2=H$, $R^3=COOH$, $R^4=(CH_2)_4NH_2$).

According to the procedure described in example 18, starting from benzyl N-benzyloxycarbonyl-S-octadecyl-L-cysteinyl- ϵ -N-benzyloxycarbonyl-L-lysinate, the
10 title compound was prepared (95 % yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.17$

N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.30
(m, 30H); 1.49-2.02 (complex signal, 8H); 2.65 (t, 2H);
15 2.89 (dd, 1H); 2.84 (t, 2H); 3.18 (dd, 1H); 4.16 (m,
1H); 4.44 (m, 1H).

EXAMPLE 21

S-Octadecyl-D-cysteinyl-D-lysine (hydrobromide)

((I), X=S, $R^1=(CH_2)_{17}CH_3$, $R^2=H$, $R^3=COOH$, $R^4=(CH_2)_4NH_2$).

20 According to the procedure described in example 18, starting from benzyl N-benzyloxycarbonyl-S-octadecyl-D-cysteinyl- ϵ -N-benzyloxycarbonyl-D-lysinate, the title compound was prepared (88 % yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
25 $R_f=0.17$

N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.84 (t, 3H); 1.30
(m, 30H); 1.49-2.02 (complex signal, 8H); 2.65 (t, 2H);
2.89 (dd, 1H); 2.84 (t, 2H); 3.18 (dd, 1H); 4.16 (m,
1H); 4.44 (m, 1H).

EXAMPLE 22

30 S-Octadecyl-L-cysteinyl-D-lysine (hydrobromide)

((I), $X=S$, $R^1=(CH_2)_{17}CH_3$, $R^2=H$, $R^3=COOH$, $R^4=(CH_2)_4NH_2$).

According to the procedure described in example 18, starting from benzyl N-benzyloxycarbonyl-S-octadecyl-L-cysteinyl-~~E~~-N-benzyloxycarbonyl-D-lysinate, the title compound was prepared as a colourless oil (97 % yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.17$

N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.30 (m, 30H); 1.49-2.02 (complex signal, 8H); 2.65 (t, 2H); 2.89 (dd, 1H); 2.84 (t, 2H); 3.18 (dd, 1H); 4.16 (m, 1H); 4.44 (m, 1H).

EXAMPLE 23

S-Butyl-D-cysteinyl-L-glutamic acid (hydrobromide)

((I), $X=S$, $R^1=(CH_2)_3CH_3$, $R^2=H$, $R^3=COOH$, $R^4=CH_2CH_2COOH$).

According to the procedure described in example 18, starting from benzyl N-benzyloxycarbonyl-S-butyl-D-cysteinyl-~~X~~-benzyl-L-glutamate, the title compound was prepared (92 % yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.18$

N.M.R. 1H (300 MHz, $CDCl_3$) δ ppm: 0.82 (t, 3H); 1.30 (m, 2H); 1.51 (m, 2H); 1.98 (m, 1H); 2.21 (m, 1H); 2.49 (t, 2H); 2.58 (t, 2H); 3.02 (m, 2H); 4.20 (t, 2H); 4.45 (m, 1H).

EXAMPLE 24

S-Butyl-D-cysteinyl-L-leucine (hydrobromide)

((I), $X=S$, $R^1=(CH_2)_3CH_3$, $R^2=H$, $R^3=COOH$, $R^4=CH_2CH(CH_3)_2$).

According to the procedure described in example 18, starting from benzyl N-benzyloxycarbonyl-S-butyl-D-

cysteinyl-L-leucinate, the title compound was prepared (98 % yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.38$

5 N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.80 (m, 9H); 1.28 (m, 2H); 1.68 (m, 3H); 2.54 (m, 2H); 3.03 (m, 2H); 4.31 (m, 2H).

EXAMPLE 25

S-Butyl-D-cysteinyl-L-lysine (hydrobromide)

10 ((I), $\text{X}=\text{S}$, $\text{R}^1=(\text{CH}_2)_3\text{CH}_3$, $\text{R}^2=\text{H}$, $\text{R}^3=\text{COOH}$, $\text{R}^4=(\text{CH}_2)_4\text{NH}_2$).

According to the procedure described in example 18, starting from benzyl N-benzyloxycarbonyl-S-butyl-D-cysteinyl-~~6~~-N-benzyloxycarbonyl-L-lysinate, the title compound was prepared (91 % yield).

15 T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.24$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.94 (t, 3H); 1.39-2.00 (complex signal, 10H); 2.67 (t, 2H); 2.96 (m, 3H); 3.14 (dd, 1H); 4.19 (t, 1H); 4.43 (m, 1H).

20

EXAMPLE 26

N-Acetyl-S-octadecyl-D-cysteinyl-L-glutamic acid

((I), $\text{X}=\text{S}$, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2=\text{COCH}_3$, $\text{R}^3=\text{COOH}$, $\text{R}^4=\text{CH}_2\text{CH}_2\text{COOH}$).

A mixture of benzyl S-octadecyl-D-cysteinyl-L-glutaminate (hydrobromide) (0.270 g, 0.40 mmol), acetic anhydride (0.038 ml, 0.40 mmol), triethylamine (0.067 ml, 0.48 mmol) and dry benzene (8 ml) is stirred at room temperature for 4 h. After that, the mixture is evaporated to dryness, diluted with chloroform (25 ml),
25 washed with 0.2 M hydrochloric acid, dried and solvent
30 is removed, to obtain a crude product, which is redis-

solved in a solution of hydrobromic acid in 33% acetic acid. The mixture is left under stirring at room temperature for 4 h. After that the mixture is evaporated to dryness, to obtain a crude product which is purified by
5 flash chromatography on a functionalized silica gel column (SDS RP-18, 200-400 mesh). Eluting with water (0.045% trifluoroacetic acid):acetonitrile (0.035% trifluoroacetic acid), 2:3, 0.187 g of the title compound are recovered as a white solid melting at 118-120°C
10 (86% yield).

$[\alpha]_D^{20} = +11.4^\circ$ (c=0.440, methanol).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f = 0.15$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.92 (t, 3H); 1.29
15 (m, 30H); 1.58 (m, 2H); 1.97 (m, 1H); 2.00 (s, 3H);
2.19 (m, 1H); 2.43 (t, 2H); 2.56 (t, 2H); 2.73 (dd, 1H); 2.92 (dd, 1H); 4.44 (m, 1H); 4.55 (m, 1H).

EXAMPLE 27

N-Acetyl-S-octadecyl-D-cysteiny-L-leucine

20 ((I), X=S, $\text{R}^1 = (\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2 = \text{COCH}_3$, $\text{R}^3 = \text{COOH}$,
 $\text{R}^4 = \text{CH}_2\text{CH}(\text{CH}_3)_2$).

According to the procedure described in example 26, starting from benzyl S-octadecyl-D-cysteiny-L-leucinate, the title compound was prepared as a white solid melting at 95-97°C (73 % yield).
25

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f = 0.54$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.81 (t, 6H); 1.20
(m, 30H); 1.52 (m, 5H); 1.92 (s, 3H); 2.46 (t, 2H);
30 2.74 (m, 2H); 4.43 (m, 2H).

EXAMPLE 28

N-Acetyl-S-octadecyl-D-cysteinyglycine

((I), X=S, $R^1=(CH_2)_{17}CH_3$, $R^2=COCH_3$, $R^3=COOH$, $R^4=H$).

A mixture of S-octadecyl-D-cysteinyglycine
 5 (hydrobromide) (0.102 g, 0.24 mmol), acetic anhydride
 (0.030 ml, 0.31 mmol), triethylamine (0.084 ml, 0.60
 mmol) and dry benzene (10 ml) is stirred at room tempe-
 rature for 4 h. After that the mixture is evaporated to
 dryness, diluted with chloroform (25 ml), washed with
 10 0.2 M hydrochloric acid, dried and solvent is removed,
 to obtain a crude product which is purified by flash
 chromatography on a functionalized silica gel column
 (SDS RP-18, 200-400 mesh). Eluting with water (0.045%
 trifluoroacetic acid):acetonitrile (0.035% trifluoroa-
 15 cetic acid), 1:1, 0.092 g of the title compound are re-
 covered as a semisolid oil (81% yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.42$

N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.89 (t, 3H); 1.33
 20 (m, 30H); 1.54 (m, 2H); 2.01 (s, 3H); 2.55 (t, 2H);
 2.73 (dd, 1H); 3.00 (dd, 1H); 3.90 (s, 2H); 4.55 (m,
 1H).

EXAMPLE 29

N-Acetyl-S-octadecyl-D-cysteinyglycine-~~6~~-N-acetyl-L-lysine

25 ((I), X=S, $R^1=(CH_2)_{17}CH_3$, $R^2=COCH_3$, $R^3=COOH$,
 $R^4=(CH_2)_4NHC(=O)CH_3$).

According to the procedure described in example
 28, starting from S-octadecyl-D-cysteinyglycine-L-lysine
 (hydrobromide), the title compound was prepared as a
 30 semisolid oil (67 % yield).

$[\alpha]_D^{20} = +4.5^\circ$ (c=0.964, methanol).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,

$R_f=0.21$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.29 (m, 30H); 1.34-1.64 (complex signal, 6H); 1.73 (m, 1H);
 5 1.89 (m, 1H); 1.92 (s, 3H); 2.02 (s, 3H); 2.56 (t, 2H);
 2.74 (dd, 1H); 2.92 (dd, 1H); 3.14 (t, 2H); 4.39 (m, 1H); 4.58 (t, 1H).

EXAMPLE 30

N-Acetyl-S-octadecyl-L-cysteinyl- ϵ -N-acetyl-L-lysine

10 ((I), X=S, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2=\text{COCH}_3$, $\text{R}^3=\text{COOH}$,
 $\text{R}^4=(\text{CH}_2)_4\text{NHCOCH}_3$).

According to the procedure described in example 28, starting from S-octadecyl-L-cysteinyl-L-lysine (hydrobromide), the title compound was prepared as a
 15 solid melting at 120-122°C (72 % yield).

$[\alpha]_D^{20} = -5.9^\circ$ (c=0.720, chloroform:methanol, 3:2).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,

$R_f=0.21$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.29
 20 (m, 30H); 1.34-1.64 (complex signal, 6H); 1.73 (m, 1H);
 1.89 (m, 1H); 1.92 (s, 3H); 1.84 (s, 3H); 2.56 (t, 2H);
 2.71 (dd, 1H); 2.95 (dd, 1H); 3.15 (m, 2H); 4.38 (m, 1H); 4.52 (m, 1H).

EXAMPLE 31

25 N-Acetyl-S-octadecyl-D-cysteinyl- ϵ -N-acetyl-D-lysine

((I), X=S, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2=\text{COCH}_3$, $\text{R}^3=\text{COOH}$,
 $\text{R}^4=(\text{CH}_2)_4\text{NHCOCH}_3$).

According to the procedure described in example 28, starting from S-octadecyl-D-cysteinyl-D-lysine (hydrobromide), the title compound was prepared as a
 30 white solid melting at 122-125°C (76 % yield).

$[\alpha]_D^{20} = +6.9^\circ$ ($c=0.865$, chloroform:methanol, 3:2).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.21$

5 N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.29 (m, 30H); 1.34-1.64 (complex signal, 6H); 1.73 (m, 1H); 1.89 (m, 1H); 1.92 (s, 3H); 2.00 (s, 3H); 2.56 (t, 2H); 2.71 (dd, 1H); 2.95 (dd, 1H); 3.15 (m, 2H); 4.38 (m, 1H); 4.52 (m, 1H).

EXAMPLE 32

10 N-Acetyl-S-octadecyl-L-cysteinyl- ϵ -N-acetyl-D-lysine
 ((I), X=S, $R^1=(CH_2)_{17}CH_3$, $R^2=COCH_3$, $R^3=COOH$,
 $R^4=(CH_2)_4NHCOCH_3$).

According to the procedure described in example 28, starting from S-octadecyl-L-cysteinyl-D-lysine
 15 (hydrobromide), the title compound was prepared as a white solid melting at 82-85°C (70 % yield).

$[\alpha]_D^{20} = -6.7^\circ$ ($c=0.72$, methanol).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.21$

20 N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.29 (m, 30H); 1.34-1.64 (complex signal, 6H); 1.73 (m, 1H); 1.89 (m, 1H); 1.92 (s, 3H); 2.02 (s, 3H); 2.56 (t, 2H); 2.74 (dd, 1H); 2.92 (dd, 1H); 3.14 (t, 2H); 4.39 (m, 1H); 4.58 (t, 1H).

EXAMPLE 33

25 N-Dodecanoyl-S-butyl-D-cysteinyl-L-glutamic acid
 ((I), X=S, $R^1=(CH_2)_3CH_3$, $R^2=CO(CH_2)_{10}CH_3$, $R^3=COOH$,
 $R^4=CH_2CH_2COOH$).

A mixture of S-butyl-D-cysteinyl-L-glutamic acid
 30 (hydrobromide) (0.419 g, 1.08 mmol), dodecaneic anhydride (0.425 mg, 1.11 mmol), triethylamine (0.563 ml,

4.04 mmol) and dry chloroform (30 ml) is stirred at room temperature for 4 h. After that it is diluted with chloroform (50 ml), washed with 0.2 M hydrochloric acid, dried and solvent is removed, to obtain a crude product, which is purified by flash chromatography on a silica gel column. Eluting with chloroform:methanol, 4:1, 0.449 g of the title compound are recovered as a semisolid oil (85 % yield).

$[\alpha]_D^{20} = +22.7^\circ$ (c=3.33, methanol).

10 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.24$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.90 (m, 6H); 1.22-1.46 (complex signal, 18H); 1.56 (m, 4H); 1.96 (m, 1H); 2.18 (m, 1H); 2.25 (t, 2H); 2.40 (q, 2H); 2.55 (t, 2H); 2.73 (m, 1H); 2.93 (m, 1H); 4.44 (m, 1H); 4.56 (m, 1H).

EXAMPLE 34

N-Dodecanoyl-S-butyl-D-cysteinyl-L-leucine

((I), X=S, $\text{R}^1=(\text{CH}_2)_3\text{CH}_3$, $\text{R}^2=\text{CO}(\text{CH}_2)_{10}\text{CH}_3$, $\text{R}^3=\text{COOH}$, $\text{R}^4=\text{CH}_2\text{CH}(\text{CH}_3)_2$).

20 Following the process described in example 33, starting from S-octadecyl-L-cysteinyl-D-leucine (hydrobromide), the title compound was prepared as a semisolid oil (97 % yield).

$[\alpha]_D^{20} = +2.0^\circ$ (c=5.40, methanol).

25 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.69$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.92 (m, 12H); 1.22-1.84 (complex signal, 25H); 2.34 (t, 2H); 2.59 (t, 2H); 2.78 (dd, 1H); 2.89 (dd, 1H); 4.38 (m, 1H); 4.53 (m, 1H).

30

EXAMPLE 35

N-Acetyl-S-butyl-D-cysteinyll-~~S~~-N-acetyl-L-lysine

((I), X=S, $R^1=(CH_2)_3CH_3$, $R^2=COCH_3$, $R^3=COOH$, $R^4=(CH_2)_4NHCOCH_3$).

5 According to the procedure described in example 28, starting from S-butyl-D-cysteinyll-L-lysine (hydrobromide), the title compound was prepared as a semisolid oil (88 % yield).

$[\alpha]_D^{20} = +30.5^\circ$ (c=1.23, methanol).

10 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.29$

N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.92 (t, 3H); 1.39-1.64 (complex signal, 8H); 1.74 (m, 1H); 1.86 (m, 1H); 1.91 (s, 3H); 1.99 (s, 3H); 2.56 (t, 2H); 2.72 (dd, 1H); 2.92 (dd, 1H); 3.14 (t, 2H); 4.38 (m, 1H); 4.56 (t, 1H).

EXAMPLE 36

S-Octadecyl-D,L-cysteine (hydrobromide)

((II), X=S, $R^1=(CH_2)_{17}CH_3$, $R^6=H$).

20 Following the process described in example 18, starting from N-benzyloxycarbonyl-S-octadecyl-D,L-cysteine, the title compound was prepared as a white solid which decomposes at 230°C (95% yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.05$

25 N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.92 (t, 3H); 1.34 (m, 30H); 1.65 (m, 2H); 2.65 (t, 2H); 3.04 (dd, 1H); 3.18 (dd, 1H); 4.22 (dd, 1H).

EXAMPLE 37

30 N-Acetyl-S-octadecyl-D,L-cysteine

((II), X=S, $R^1=(CH_2)_{17}CH_3$, $R^6=COCH_3$).

Following the process described in example 28, starting from S-Octadecyl-D,L-cysteine (hydrobromide), the title compound was prepared as a white solid melting at 96-99°C (87% yield).

5 T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.53$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.85 (t, 3H); 1.25 (m, 30H); 1.55 (m, 2H); 2.06 (s, 3H); 2.50 (t, 2H); 2.99 (m, 2H); 4.72 (m, 1H).

10

EXAMPLE 38

N-Acetyl-S-octadecyl-D,L-cysteinytaurine (sodium salt).

((I), $\text{X}=\text{S}$, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2=\text{COCH}_3$, $\text{R}^3=\text{H}$, $\text{R}^4=\text{CH}_2\text{SO}_3\text{Na}$).

A solution of N-acetyl-S-octadecyl-D,L-cysteine
15 (0.231 g, 0.55 mmol) and N-hydroxy-5-norbornen-2,3-dicarboximide acid (0.109 g, 0.61 mmol) in tetrahydrofuran:dioxane, 1:1 (6 ml), is added at 0°C with dicyclohexylcarbodiimide (0.127 g, 0.61 mmol). The mixture is stirred for 2 h at 0°C and for 20 h at room temperature.
20 After that, the formed dicyclohexylurea is filtered off and the filtrate is evaporated to dryness. The resulting residue is redissolved in dioxane (2.5 ml) and added with a solution of taurine (0.078 g, 0.62 mmol) in a 0.42 M sodium bicarbonate solution (1.5 ml).
25 The mixture is stirred for 20 h at room temperature, evaporated to dryness and the resulting crude product is digested with ethyl acetate. The insoluble residue is dissolved in chloroform (300 ml), washed with 2 M hydrochloric acid and dried and solvent is removed, to
30 obtain a crude product which is purified by flash chromatography on a functionalized silica gel column (SDS

RP-18, 200-400 mesh). Eluting with water (0.045% trifluoroacetic acid):acetonitrile (0.035% trifluoroacetic acid), 3:2, 0.234 g of the title compound are recovered as a white solid which decomposes at 168°C (78% yield).

5 T.L.C.: eluent chloroform:methanol:water, 65:25:4, $R_f=0.24$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.89 (t, 3H); 1.29 (m, 30H); 1.58 (m, 2H); 1.92 (s, 3H); 2.55 (t, 2H); 2.71 (m, 1H); 2.96 (m, 3H); 3.59 (m, 2H); 4.44 (m, 1H).

10

EXAMPLE 39

1-O-Octadecyl-2-acetylamino-3-deoxyglycerol.

((XI), $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^6=\text{COCH}_3$).

Following the process described in example 28, starting from 1-O-octadecyl-2-amino-3-deoxyglycerol the title compound was prepared as a white solid melting at 71-72°C (90% yield).

15

T.L.C.: eluent chloroform:methanol, 9:1, $R_f=0.43$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.85 (t, 3H); 1.24 (m, 30H); 1.55 (m, 2H); 2.00 (s, 3H); 3.40 (t, 2H); 3.50-3.68 (complex signal, 3H); 3.80 (dd, 1H); 4.03 (m, 1H).

20

EXAMPLE 40

N-Acetyl-O-octadecyl-D,L-serine. ((II), X=O, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^6=\text{COCH}_3$).

25

A solution of 1-O-octadecyl-2-acetylamino-3-deoxyglycerol (0.398 g, 1.03 mmol) in carbon tetrachloride:acetonitrile:water, 1:1:1.4 (37 ml) is added with NaIO_4 (0.909 g, 4.24 mmol) and $\text{RuCl}_3 \cdot 3\text{H}_2\text{O}$ (8.2 mg, 0.031 mmol). The mixture is stirred for 1.5 h at room temperature. After that, water (7 ml) and methylene chloride (7 ml) are added, the two formed phases are

30

separated and the aqueous one is extracted with methylene chloride. The combined organic phases are dried and solvent is removed, to obtain a crude product which is purified by flash chromatography on silica gel column. Eluting with chloroform:methanol, 97.5:2.5, 0.346 g of the title compound are recovered as a white solid melting at 86-89°C (82% yield).

T.L.C.: eluent chloroform:methanol:water, 64:25:4, $R_f=0.35$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.85 (t, 3H); 1.25 (m, 30H); 1.52 (m, 2H); 2.02 (s, 3H); 3.42 (t, 2H); 3.62 (dd, 1H); 3.86 (dd, 1H); 4.68 (m, 1H).

EXAMPLE 41

N-Acetyl-O-octadecyl-D,L-serinyl- γ -benzyl-L-glutamate.

((IV), X=O, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^6=\text{COCH}_3$, $\text{R}^7=\text{COOCH}_2\text{C}_6\text{H}_5$, $\text{R}^8=\text{CH}_2\text{CH}_2\text{COOCH}_2\text{C}_6\text{H}_5$).

According to the procedure described in example 6, starting from N-acetyl-O-octadecyl-D,L-serine and L-glutamic acid dibenzyl ester (p-toluenesulfonate), the title compound was prepared as a colourless oil (83% yield).

T.L.C.: eluent chloroform:methanol, 9:1, $R_f = 0.54$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.85 (t, 3H); 1.25 (m, 30H); 1.50 (m, 2H); 1.99 (m, 1H); 2.00 (s, 3H); 2.21 (m, 1H); 2.38 (m, 2H); 3.39 (m, 3H); 3.76 (dd, 1H); 4.51 (m, 1H); 4.63 (m, 1H); 5.08 (s, 2H); 5.12 (s, 2H); 7.32 (m, 10H).

EXAMPLE 42

N-Acetyl-O-octadecyl-D,L-serinyl-L-leucinate ((IV),

X=O, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^6=\text{COCH}_3$, $\text{R}^7=\text{COOCH}_2\text{C}_6\text{H}_5$, $\text{R}^8=\text{CH}_2\text{CH}(\text{CH}_3)_2$).

According to the procedure described in example 6, starting from N-acetyl-O-octadecyl-D,L-serine and benzyl L-leucinate (hydrochloride), the title compound was prepared as a colourless oil (92 % yield).

5 T.L.C.: eluent chloroform:methanol:water, 64:25:4,
 $R_f=0.50$

N.M.R. ^1H (300 MHz, CDCl_3) δ ppm: 0.87 (m, 9H); 1.21 (m, 30H); 1.61 (m, 5H); 1.98 (s, 3H); 3.42 (m, 3H); 3.78 (m, 1H); 4.50 (m, 1H); 4.62 (m, 1H); 5.12 (s, 2H);
 10 7.32 (m, 5H).

EXAMPLE 43

N-Acetyl-O-octadecyl-D,L-serinyl-L-glutamic acid

((I), $\text{X}=\text{O}$, $\text{R}^1=(\text{CH}_2)_{17}\text{CH}_3$, $\text{R}^2=\text{COCH}_3$, $\text{R}^3=\text{COOH}$,
 $\text{R}^4=\text{CH}_2\text{CH}_2\text{COOH}$).

15 A solution of benzyl N-acetyl-O-octadecyl-D,L-serinyl- γ -benzyl-L-glutamate (0.100 g, 0.14 mmol) in glacial acetic acid (10 ml) is added with 0.015 g of 10% palladium-on-carbon and the mixture is stirred for 18 h at room temperature, under hydrogen atmosphere, then it
 20 is filtered and evaporated to dryness, to obtain a crude product which is purified by flash chromatography on a functionalized silica gel column (SDS RP-18, 200-400 mesh). Eluting with water (0.045% trifluoroacetic acid):acetonitrile (0.035% trifluoroacetic acid), 2:3,
 25 0.056 g of the title compound are recovered as a semi-solid oil (73 % yield).

T.L.C.: eluent chloroform:methanol:water, 65:25:4,
 $R_f=0.14$

N.M.R. ^1H (300 MHz, CD_3OD) δ ppm: 0.90 (t, 3H); 1.28 (m, 30H); 1.56 (m, 2H); 1.95 (m, 1H); 2.02 (s, 3H);
 30 2.20 (m, 1H); 2.41 (m, 2H); 3.46 (m, 2H); 3.65 (m, 2H);

4.46 (m, 1H); 4.58 (m, 1H).

EXAMPLE 44

N-Acetyl-O-octadecyl-D,L-serinyl-L-leucine

((I), X=O, $R^1=(CH_2)_{17}CH_3$, $R^2=COCH_3$, $R^3=COOH$,
 5 $R^4=CH_2CH(CH_3)_2$).

According to the procedure described in example 43, starting from benzyl N-acetyl-O-octadecyl-D,L-serinyl-L-leucinate, the title compound was prepared as a semisolid oil (93 % yield).

10 T.L.C.: eluent chloroform:methanol:water, 64:25:4,
 $R_f=0.65$

N.M.R. 1H (300 MHz, CD_3OD) δ ppm: 0.92 (m, 9H); 1.29 (m, 30H); 1.49-1.74 (complex signal, 5H); 2.00 (s, 3H); 3.46 (m, 2H); 3.65 (m, 2H); 4.45 (m, 1H); 4.58 (m, 1H).

15

EXAMPLE 45

Determination of the inhibition on phospholipase A_2 .

The PLA_2 activity is determined by radioactive evaluation of the labelled fatty acid which esterifies the sn-2 position of the phospholipid substrate and which is released by the enzyme action. E. coli phospholipid membranes, to which labelled oleic acid ($1-14_C$) has previously been incorporated, are used as the substrate. The used enzyme is purified PLA_2 from human synovial liquid.

25

The reaction mixture contains 25 mM Hepes buffer (pH 7.0), 5.0 mM Ca^{2+} and 1.4×10^6 E. coli autoclaved (corresponding to 10000 dpm and 10.0 nmol of phospholipid). The reaction is started by addition of 80 ng of purified enzyme, keeping stirring for 5 minutes at 37°C. The reaction is stopped by adding 3.0 ml of $CHCl_3:CH_3OH$ (1:2 v/v), the lipids are extracted by the

30

Bligh and Dyer procedure and the reaction products are separated by thin layer chromatography and dpm are quantified by liquid scintillation.

The study of the inhibiting effect on PLA₂ on the compounds of the present invention is carried out dissolving them in dimethylsulfoxide or ethanol and adding them to the above described reaction mixture until the required proportion. The hydrolysis percentage is calculated by means of the following equation:

$$\% \text{ Hydrolysis} = \frac{\text{free fatty acid (dpm)}}{\text{non hydrolyzed phospholipid+free fatty acid (dpm)}}$$


The compounds of the present invention were tested according to this procedure. The inhibiting action of the different compounds is expressed as the product concentration inhibiting the activity of the enzyme by 50% compared with the control in the absence of inhibitor (IC₅₀). Some examples of the obtained results are reported in the following Table.

Inhibiting effect on PLA₂ from human synovial liquid

	Compound of Example N°	IC ₅₀ (μM)
	26	20
25	27	30
	29	15
	28	15
	34	25
	38	15
30	43	20
	44	20

CLAIMS

1. Compounds of general formula (I)



I


10 wherein:

- X is an oxygen or sulphur atom;
- R^1 is a C_4 - C_{20} straight or branched alkyl group;
- R^2 is hydrogen or a R^5 -CO-, R^5 -O-CO- or R^5 -SO₂-group, in which R^5 is a C_1 - C_{20} straight or branched
- 15 alkyl group, phenyl or an arylalkyl group of less than 20 carbon atoms totally;
- R^3 is hydrogen, a carboxy group, an alkoxycarbonyl, aryloxy carbonyl or arylalkoxycarbonyl group of less than 10 carbon atoms in the last three cases;
- 20 - R^4 is hydrogen, a C_1 - C_6 straight or branched alkyl group, an arylalkyl group of less than 10 carbon atoms, an heteroarylalkyl group of less than 10 carbon atoms, an hydroxyalkyl group of less than 4 carbon atoms, a thioalkyl or alkylthioalkyl group of less than 4 carbon
- 25 atoms, an aminoalkyl group of less than 6 carbon atoms, the amino group being in the free or derivatized form, as an alkyl amide of less than 4 carbon atoms, a C_2 - C_5 carboxyalkyl group, the carboxy group being in the free or derivatized form as an alkyl or aralkyl ester of
- 30 less than 8 carbon atoms, a carbamoylalkyl group of less than 4 carbon atoms, a guanidinoalkyl group of

less than 5 carbon atoms, or a sulfoalkyl group of less than 4 carbon atoms; with the proviso that R^4 cannot be hydrogen when R^3 is hydrogen or when R^1 is C_4 alkyl and R^2 is hydrogen or acetyl;

5 and the pharmaceutically acceptable salts thereof.


2. Compounds according to claim 1 characterized in that R^3 is hydrogen or a carboxy group, R^4 is a sulfo-methyl group, or the group



in formula (I) is an amino acid selected from glycine, lysine with the ϵ -amino in the free or alkylcarbonylamino form of less than 4 carbon atoms, leucine or glutamic acid with the γ -carboxyl in the free or alkoxy-carbonyl or arylalkoxycarbonyl form of less than 8 carbon atoms.

3. Compounds according to claim 2 characterized in that R^2 is hydrogen or a R^5CO- group, wherein R^5 is a C_1-C_{20} straight alkyl group.

4. Compounds according to claim 3 characterized in that the group



in formula (I) is an amino acid selected from glycine, lysine with the ϵ -amino in the free or alkylcarbonylamino form of less than 4 carbon atoms, leucine or glutamic acid with the γ -carboxyl in the free or alkoxy-carbonyl or arylalkoxycarbonyl form of less than 8 carbon atoms.

5. Compounds according to claim 3 characterized in

that R^3 is hydrogen and R^4 is a sulfomethyl group.

6. As compounds according to claim 1:

N-acetyl-O-octadecyl-D,L-serinyl-L-glutamic acid;

N-acetyl-O-octadecyl-D,L-serinyl-L-leucine;

5 S-octadecyl-D-cysteinylglycine (hydrobromide);

S-octadecyl-D-cysteinyl-L-lysine (hydrobromide);

S-octadecyl-L-cysteinyl-L-lysine (hydrobromide);

S-octadecyl-D-cysteinyl-D-lysine (hydrobromide);

S-octadecyl-L-cysteinyl-D-lysine (hydrobromide);

10 S-butyl-D-cysteinyl-L-glutamic acid (hydrobromide);

S-butyl-D-cysteinyl-L-leucine (hydrobromide);

S-butyl-D-cysteinyl-L-lysine (hydrobromide);

N-acetyl-S-octadecyl-D-cysteinyl-L-leucine;

N-acetyl-S-octadecyl-D-cysteinylglycine;

15 N-acetyl-S-octadecyl-D-cysteinyl- ϵ -N-acetyl-L-lysine;

N-acetyl-S-octadecyl-L-cysteinyl- ϵ -N-acetyl-L-lysine;

N-acetyl-S-octadecyl-D-cysteinyl- ϵ -N-acetyl-D-lysine;

N-acetyl-S-octadecyl-L-cysteinyl- ϵ -N-acetyl-D-lysine;

N-dodecanoyl-S-butyl-D-cysteinyl-L-glutamic acid;


20 N-dodecanoyl-S-butyl-D-cysteinyl-L-leucine;

N-acetyl-S-butyl-D-cysteinyl- ϵ -N-acetyl-L-lysine;

N-acetyl-S-octadecyl-D,L-cysteinyltaurine (sodium salt).


7. A process for the preparation of compounds of general formula (I) wherein R_4 is different from a sulfoalkyl group, comprising the reaction of a compound of formula (II) of suitable stereochemistry at the 2-carbon

42




II

wherein X and R¹ have the same meanings as in claim 1 and R₆ has the same meanings as R₂ or, if R₂ is hydrogen, R₆ is a suitable amino-protecting group; with a compound of formula (III):



III

wherein R₇ and R₈ are the same as R₃ and R₄ as defined in claim 1, respectively, or they are groups which can be converted into R₃ and R₄, to give a compound of formula (IV):




IV


which is converted into compounds (I) by removing the optional protective groups in R₆, R₇ and R₈ groups.

8. A process for the preparation of compounds of general formula (I) wherein R₄ is a sulfoalkyl group and R₃ is hydrogen, comprising the reaction of a compound (II) as defined in claim 7 with a carboxy-activating agent in the presence of a dehydrating agent, followed

by reaction with a compound (V)



wherein R_4 is a sulfoalkyl group of less than 4 carbon atoms, to give a compound of formula (VI)



VI

wherein X, R^1 , R^4 and R^6 are as defined in the previous claims, which compound (VI) is then converted to compounds (I) by removing the optionally present protecting groups.

9. The use of the compounds of claims 1 to 6 for the preparation of a medicament for the therapeutical treatment of inflammatory and allergic diseases, rheumatoid arthritis, tendinitis, bursitis, psoriasis, bronchial asthma and the like.

International Application No.

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C07K5/06; C07C323/60; A61K37/02; A61K31/16																		
II. FIELDS SEARCHED <div style="text-align: center;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%;">Classification System</td> <td style="width: 75%;">Classification Symbols</td> </tr> <tr> <td>Int.Cl. 5</td> <td>C07K ; C07C</td> </tr> </table> <div style="text-align: center;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>				Classification System	Classification Symbols	Int.Cl. 5	C07K ; C07C											
Classification System	Classification Symbols																	
Int.Cl. 5	C07K ; C07C																	
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 5%;">Category ^o</th> <th style="width: 75%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="text-align: center;">X</td> <td>DE,A,2 728 462 (TAKEDA CHEMICAL INDUSTRIES) 5 January 1978 see reference example 4 on page 13 ff. ---</td> <td style="text-align: center;">1,2,7</td> </tr> <tr> <td style="text-align: center;">X</td> <td>GB,A,1 417 318 (AKZO) 10 December 1975 see examples 1.A.1.-1.A.2. ---</td> <td style="text-align: center;">1,7</td> </tr> <tr> <td style="text-align: center;">X</td> <td>DE,A,1 964 798 (CIBA) 16 July 1970 see example 3 ---</td> <td style="text-align: center;">1,7</td> </tr> <tr> <td colspan="3" style="text-align: center;">-/-</td> </tr> </table>				Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	DE,A,2 728 462 (TAKEDA CHEMICAL INDUSTRIES) 5 January 1978 see reference example 4 on page 13 ff. ---	1,2,7	X	GB,A,1 417 318 (AKZO) 10 December 1975 see examples 1.A.1.-1.A.2. ---	1,7	X	DE,A,1 964 798 (CIBA) 16 July 1970 see example 3 ---	1,7	-/-		
Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																
X	DE,A,2 728 462 (TAKEDA CHEMICAL INDUSTRIES) 5 January 1978 see reference example 4 on page 13 ff. ---	1,2,7																
X	GB,A,1 417 318 (AKZO) 10 December 1975 see examples 1.A.1.-1.A.2. ---	1,7																
X	DE,A,1 964 798 (CIBA) 16 July 1970 see example 3 ---	1,7																
-/-																		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> ^o Special categories of cited documents : ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </div> <div style="width: 45%;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family </div> </div>																		
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;"> Date of the Actual Completion of the International Search <div style="text-align: center;">18 AUGUST 1993</div> </td> <td style="width: 50%;"> Date of Mailing of this International Search Report <div style="text-align: center;">02-09-1993</div> </td> </tr> <tr> <td> International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td> Signature of Authorized Officer <div style="text-align: center;">FUHR C.K.</div> </td> </tr> </table>				Date of the Actual Completion of the International Search <div style="text-align: center;">18 AUGUST 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">02-09-1993</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">FUHR C.K.</div>											
Date of the Actual Completion of the International Search <div style="text-align: center;">18 AUGUST 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">02-09-1993</div>																	
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">FUHR C.K.</div>																	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	<p>ORGANIC SYNTHESSES vol. 59, 1979, pages 159 - 169 A.M. FELIX ET AL. 'Removal of N-alpha-Benzylloxycarbonyl Groups from Sulfur-containing Peptides by Catalytic Hydrogenation in Liquid Ammonia: O-tert-Bu tyl-L-Seryl-S-tert-Butyl-L-Cysteine tert-Butyl Ester' see formulas on page 159 see page 161, paragraph 2 - page 162, paragraph 1 see note 11 on pages 163-165</p>	1,7
X	<p>--- CHEMICAL AND PHARMACEUTICAL BULLETIN vol. 26, no. 5, May 1978, TOKYO JP pages 1576 - 1585 O. NISHIMURA ET AL. 'New Method for Removing the S-p-Methoxybenzyl and S-t-Butyl Groups from Cysteine Residues with Mercuric Trifluoroacetate' see page 1581, paragraph 5 see page 1581, paragraph 8</p>	1,2,7
X	<p>--- ACTA CHIMICA HUNGARICA vol. 122, no. 3-4, July 1986, BUDAPEST HU pages 261 - 272 I. PAVO ET AL. 'A NEW SYNTHESIS OF SOMATOSTATIN AND SOME POTENTIAL METABOLITES' see table I on pages 266 and 267 compounds 24-27</p>	1
X	<p>--- JOURNAL OF ORGANIC CHEMISTRY vol. 46, no. 9, April 1981, EASTON US pages 1868 - 1873 J.J. PASTUSZAK AND A. CHIMIAK 'tert-Butyl Group as Thiol Protection in Peptides Synthesis' see page 1869, right column, paragraph 4 see page 1872, left column, paragraph 3 -paragraph 4</p>	1,7
X	<p>--- BIOPOLYMERS vol. 22, no. 12, December 1983, pages 2523 - 2538 P. PALLAI ET AL. 'Extended Retro-Inverso Analog of Somatostatin' see page 2530, paragraph 3 - page 2531, paragraph 1 see page 2534, paragraph 3 - page 2535, paragraph 1</p>	1-4,7
	<p>--- -/--</p>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	PEPTIDES vol. 11, no. 5, 1990, pages 983 - 988 G.A. GACEL ET AL. 'Synthesis, Biochemical and Pharmacological Properties of BUBUC, a highly Selective and Systemically Active Agonist for In Vivo Studies of delta-Opioid Receptors' see page 984, right column, paragraph 2 -paragraph 3 ---	1-4,7
X	INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH vol. 38, no. 6, December 1991, COPENHAGEN DK pages 562 - 568 K. BARLOS ET AL. 'Solid phase synthesis of partially protected and free peptides containing disulphide bonds by simultaneous cysteine oxidation-release from 2-chlorotrityl resin' see page 567, left column, line 8 -----	1

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9300866
SA 72814

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18/08/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-2728462	05-01-78	CH-A- 628330	26-02-82
		SE-A- 7707387	29-12-77
		US-A- 4111924	05-09-78
GB-A-1417318	10-12-75	CA-A- 1010022	10-05-77
		CH-A- 591428	15-09-77
		DE-A, C 2305727	16-08-73
		FR-A, B 2171188	21-09-73
		JP-C- 1233776	17-10-84
		JP-A- 48091031	27-11-73
		JP-B- 59005578	06-02-84
		NL-A- 7201604	10-08-73
		SE-B- 392612	04-04-77
		US-A- 3835110	10-09-74
DE-A-1964798	16-07-70	BE-A- 744083	06-07-70
		FR-A- 2034455	11-12-70
		NL-A- 7000105	09-07-70